Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Decline in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 5,752 shares, a decrease of 99.4% from the October 15th total of 919,936 shares. Currently, 4.5% of the company’s stock are short sold. Based on an average daily volume of 48,213 shares, the days-to-cover ratio is presently 0.1 days.

Biodexa Pharmaceuticals Stock Performance

Biodexa Pharmaceuticals stock traded down $0.02 during mid-day trading on Thursday, reaching $2.38. 10,221 shares of the company’s stock were exchanged, compared to its average volume of 216,440. The business’s fifty day simple moving average is $4.71 and its 200 day simple moving average is $22.62. Biodexa Pharmaceuticals has a one year low of $2.28 and a one year high of $357.60.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a specialty pharmaceutical company focused on developing and commercializing therapies for rare and difficult-to-treat diseases, with an emphasis on oncology and neurological conditions. The company’s programs are designed to address areas where existing treatment options are limited. Biodexa has developed drug-delivery technologies intended to improve the administration, targeting and duration of pharmaceutical treatments. Its portfolio has included Q-Sphera, a platform for producing long-acting injectable medicines, as well as development programs involving therapies delivered directly to tumors or the central nervous system.